Mammalian Target of Rapamycin as a Therapeutic Target in Leukemia

Publisher： Bentham Science Publishers

E-ISSN： 1875-5666|5|7|653-661

ISSN： 1566-5240

Source： Current Molecular Medicine, Vol.5, Iss.7, 2005-11, pp. : 653-661

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Editorial [Hot Topic: Mammalian Target of Rapamycin as a Therapeutic Target in Leukemia (Executive Editors: Francis J. Giles / Maher Albitar)]

By  

Current Molecular Medicine, Vol. 5, Iss. 7, 2005-11 ,pp. : 607-607

Bentham Science Publishers

Access to resources Recommend Favorite

Role of Mammalian Target of Rapamycin in Atherosclerosis

By  

Current Molecular Medicine, Vol. 18, Iss. 4, 2018-05 ,pp. : 216-232

Bentham Science Publishers

Access to resources Recommend Favorite

A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL

By Decker Thomas  

Annals of Hematology, Vol. 88, Iss. 3, 2009-03 ,pp. : 221-227

Springer Publishing Company

Access to resources Recommend Favorite

TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells

By Kikushige Yoshikane   Miyamoto Toshihiro  

International Journal of Hematology, Vol. 98, Iss. 6, 2013-12 ,pp. : 627-633

Springer Publishing Company

Access to resources Recommend Favorite

Cyclooxygenase-2: a therapeutic target in angiogenesis

By Iniguez M.A.   Rodrguez A.   Volpert O.V.   Fresno M.   Redondo J.M.  

Trends in Molecular Medicine, Vol. 9, Iss. 2, 2003-02 ,pp. : 73-78

Elsevier

Access to resources Recommend Favorite